...
首页> 外文期刊>Microbiology >Colistin resistance in Escherichia coli confers protection of the cytoplasmic but not outer membrane from the polymyxin antibiotic
【24h】

Colistin resistance in Escherichia coli confers protection of the cytoplasmic but not outer membrane from the polymyxin antibiotic

机译:Colistin抗性在<斜体切换=“是”>大肠杆菌中的抗性免受多粘菌素抗生素的细胞质但不是外膜的保护

获取原文

摘要

Colistin is a polymyxin antibiotic of last resort for the treatment of infections caused by multi-drug-resistant Gram-negative bacteria. By targeting lipopolysaccharide (LPS), the antibiotic disrupts both the outer and cytoplasmic membranes, leading to bacterial death and lysis. Colistin resistance in Escherichia coli occurs via mutations in the chromosome or the acquisition of mobilized colistin-resistance ( mcr ) genes. Both these colistin-resistance mechanisms result in chemical modifications to the LPS, with positively charged moieties added at the cytoplasmic membrane before the LPS is transported to the outer membrane. We have previously shown that MCR-1-mediated LPS modification protects the cytoplasmic but not the outer membrane from damage caused by colistin, enabling bacterial survival. However, it remains unclear whether this observation extends to colistin resistance conferred by other mcr genes, or resistance due to chromosomal mutations. Using a panel of clinical E. coli that had acquired mcr ?1, –1.5, ?2, –3, ?3.2 or ?5, or had acquired polymyxin resistance independently of mcr genes, we found that almost all isolates were susceptible to colistin-mediated permeabilization of the outer, but not cytoplasmic, membrane. Furthermore, we showed that permeabilization of the outer membrane of colistin-resistant isolates by the polymyxin is in turn sufficient to sensitize bacteria to the antibiotic rifampicin, which normally cannot cross the LPS monolayer. These findings demonstrate that colistin resistance in these E. coli isolates is due to protection of the cytoplasmic but not outer membrane from colistin-mediated damage, regardless of the mechanism of resistance.
机译:Colistin是一种高含糖型抗生素,用于治疗由多药抗革兰氏阴性细菌引起的感染。通过靶向脂多糖(LPS),抗生素破坏了外部和细胞质膜,导致细菌死亡和裂解。大肠杆菌的菌炎耐药性通过染色体中的突变或获取动员的菌落抗性(MCR)基因的突变发生。这些菌落素抵抗机制均导致LPS的化学修饰,在将LPS运输到外膜之前,在细胞质膜中添加正电量的部分。我们之前已经表明,MCR-1介导的LPS改性保护细胞质但不是由Colistin引起的损伤免受外膜,从而实现细菌存活。然而,仍然不清楚该观察结果是否延伸到其他MCR基因的菌根抗性,或由于染色体突变引起的抗性。使用已经获得的临床大肠杆菌的临床大肠杆菌α1,-1.5,α2,-3,?3.2或?5,或者在MCR基因中独立地获得了多种辛抗性,我们发现几乎所有分离物都易于肥钠介导的外部,但不是细胞质的膜。此外,我们表明,通过多粘菌素的耐霉菌分离株外膜的透化性又足以使细菌敏化到抗生素利福平的细菌,这通常不能通过LPS单层。这些发现表明,这些细胞分离物中的乳霉素抗性是由于抗性机制造成的细胞质但不是外膜的保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号